FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation
eLife · 26.06.2024 · 13
DOI: 10.7554/elife.94605 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 26.06.2024. Verfasst von Chenxi Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Cecal Neoplasms, Focal Adhesion Kinase 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
BRAF V600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAF V600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a ‘just-right’ level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAF V600E -mutant adenomas/polyps in mice and patients. In Vil1-Cre;BRAF LSL-V600E/+ ; Ptk2 fl/fl mice, Fak deletion maximized BRAF V600E ’s oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAF V600E -induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a ‘just-right’ ERK signaling optimal for BRAF V600E -induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
- UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, United States.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, United States.
- Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, United States.
ORCID-Profile: Xinghua Lu, Farzad Esni, Jing Hu
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Gao, C., Ge, H., Kuan, S. F., Cai, C., Lu, X., Esni, F., Schoen, R. E., Wang, J. H., Chu, E., & Hu, J. (2024). FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation. eLife, 13. https://doi.org/10.7554/elife.94605
Vancouver
Gao C, Ge H, Kuan SF, Cai C, Lu X, Esni F, et al. FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation. eLife. 2024;13. doi:10.7554/elife.94605
BibTeX
@article{Gao2024,
author = {Gao, Chenxi and Ge, Huaibin and Kuan, Shih-Fan and Cai, Chunhui and Lu, Xinghua and Esni, Farzad and Schoen, Robert E and Wang, Jing H and Chu, Edward and Hu, Jing},
title = {FAK loss reduces BRAFV600E-induced ERK phosphorylation to promote intestinal stemness and cecal tumor formation},
journal = {eLife},
year = {2024},
volume = {13},
doi = {10.7554/elife.94605}
}
EUVIMED